Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Research & Development (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Research & Development readings, the most recent being $5.3 million for Q4 2024.

  • On a quarterly basis, Research & Development rose 24.92% to $5.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $20.0 million, a 55.12% increase, with the full-year FY2025 number at $9.1 million, down 54.43% from a year prior.
  • Research & Development hit $5.3 million in Q4 2024 for Unicycive Therapeutics, up from $3.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $12.1 million in Q4 2022 to a low of $82000.0 in Q2 2022.
  • Median Research & Development over the past 3 years was $3.8 million (2023), compared with a mean of $4.3 million.
  • The widest YoY moves for Research & Development: up 2664.63% in 2023, down 65.11% in 2023.
  • Unicycive Therapeutics' Research & Development stood at $12.1 million in 2022, then plummeted by 65.11% to $4.2 million in 2023, then increased by 24.92% to $5.3 million in 2024.
  • The last three reported values for Research & Development were $5.3 million (Q4 2024), $3.0 million (Q3 2024), and $4.9 million (Q2 2024) per Business Quant data.